New hope for tough cancers: veonetinib trial launches

NCT ID NCT05363280

Recruiting now Disease control Sponsor: Advenchen Pharmaceuticals, LLC. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests an oral drug called veonetinib (AL8326) in 80 adults with advanced small cell lung cancer, non-small cell lung cancer, or renal cell carcinoma who have already tried at least one prior treatment. The study aims to find the best dose and see if the drug can shrink tumors or slow cancer growth. Participants will take veonetinib pills daily and be monitored for side effects and response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: veonetinib (AL8326)
What this could lead to: If successful, this could provide a new treatment option for people with advanced lung or kidney cancers who have not responded to prior therapies.
What could go wrong: This is an early Phase 2 trial with only 80 participants, so results may not apply to all patients. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma renal cell carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL-CELL LUNG RENAL CELL CARCINOMA (RCC) SMALL CELL LUNG CANCER

Contacts and locations

Locations

Cleveland Clinic
RECRUITING

Cleveland, Ohio, 44195, United States
Cleveland Clinic Florida
WITHDRAWN

Weston, Florida, 33331, United States
Hospital Universitari Vall d'Hebron
RECRUITING

Barcelona, Spain
Hospital Universitario Ramón Y Cajal
RECRUITING

Madrid, Spain
Northwestern University
COMPLETED

Chicago, Illinois, 60611, United States
Siteman Cancer Center, Washington University
RECRUITING

St Louis, Missouri, 63130, United States
University of Alabama at Birmingham
RECRUITING

Birmingham, Alabama, 35294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.